Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues

Human and Experimental Toxicology

Volumn 34, Issue 5, 2015, Pages 557-560

  Schep, L J ^a   Slaughter, R J ^a   Hudson, S ^b   Place, R ^c   Watts, M ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b LGC   (United Kingdom)

^c SOUTHLAND HOSPITAL   (New Zealand)

Author keywords

Case report; psychoactive drugs; seizure; synthetic cannabinoids

Indexed keywords

BICARBONATE; CANNABINOID DERIVATIVE; CREATINE KINASE; DIAZEPAM; DRONABINOL; EDETIC ACID; LACTIC ACID; POTASSIUM; SODIUM CHLORIDE; CANNABINOID; CANNABINOID K2; STREET DRUG;

ADULT; ARTICLE; BLOOD BIOCHEMISTRY; BLOOD SAMPLING; CASE REPORT; DRUG INTOXICATION; EMERGENCY WARD; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; SMOKING; TONGUE DISEASE; TONIC CLONIC SEIZURE; URINE INCONTINENCE; VOMITING; XEROSTOMIA; YOUNG ADULT; BLOOD; CHEMICALLY INDUCED; SEIZURES; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

CANNABINOIDS; HUMANS; MALE; SEIZURES; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928181957     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327114550886     Document Type: Article

References (14)

1. Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013 ; 108: 534-544
2. Glue P, Al-Shaqsi S, Hancock D, et al. Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J. 2013 ; 126: 18-23
3. Thomas S, Bliss S, Malik M. Suicidal ideation and self-harm following K2 use. J Okla State Med Assoc. 2012 ; 105: 430-433
4. Nacca N, Vatti D, Sullivan R, et al. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013 ; 7: 296-298
5. Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013 ; 44: 360-366
6. McQuade D, Hudson S, Dargan PI, et al. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol. 2013 ; 69: 373-376
7. Mir A, Obafemi A, Young A, et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011 ; 128: e1622 - e1627
8. Freeman MJ, Rose DZ, Myers MA, et al. Ischemic stroke after use of the synthetic marijuana "spice". Neurology. 2013 ; 81: 2090-2093
9. Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2013 ; 8: 523-526
10. Centers for Disease Control and Prevention. Acute kidney injury associated with synthetic cannabinoid use - multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013 ; 62: 93-98
11. Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National poison data system in 2010. Ann Emerg Med. 2012 ; 60: 435-438
12. Hutter M, Moosmann B, Kneisel S, et al. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrom. 2013 ; 48: 885-894
13. Yeakel JK, Logan BK. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol. 2013 ; 37: 547-551
14. McGuinness TM, Newell D. Risky recreation: synthetic cannabinoids have dangerous effects. J Psychosoc Nurs Ment Health Serv. 2012 ; 50: 16-18